{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:18Z","timestamp":1794047478469,"version":"4.8.0"},"reference-count":26,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cells are in standard clinical use to treat relapsed or refractory hematologic malignancies, such as non-Hodgkin lymphoma, multiple myeloma and acute lymphoblastic leukemia. Owing to the rapidly progressing field of CAR T-cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between European centers in prevention, diagnosis and management of short- and long-term complications. To capture the current CAR T-cell management among European Society for Blood and Marrow Transplantation (EBMT) centers and to determine the medical need and specific areas for future clinical research the EBMT Transplant Complications Working Party performed a survey among 227 EBMT CAR T-cell centers. We received complete servey answers from 106 centers (47%) addressing questions in the areas of product selection, CAR T-cell logistics, management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome as well as management in later phases including prolonged cytopenias. We identified common patterns in complication management, but also significant variety in clinical management of the centers in important aspects. Our results demonstrate a high medical need for treatment harmonization and future clinical research in the following areas: treatment of steroid-refractory and very severe cytokine release syndrome\/neurotoxicity, treatment of cytopenia, early discharge and outpatient management, as well as immunoglobulin substitution.<\/jats:p>","DOI":"10.3324\/haematol.2023.284810","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:25:06Z","timestamp":1717057506000},"page":"3557-3565","source":"Crossref","is-referenced-by-count":5,"title":["Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation"],"prefix":"10.3324","volume":"109","author":[{"given":"Olaf","family":"Penack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Boreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"68216","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"68217","doi-asserted-by":"crossref","unstructured":"Bachy E, Le Gouill S, Di Blasi R. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022; 28(10):2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"68218","doi-asserted-by":"crossref","unstructured":"Bethge WA, Martus P, Schmitt M. GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022; 140(4):348-358.","DOI":"10.1182\/blood.2021015209"},{"key":"68219","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason J. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022; 399(10343):2294.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"68220","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"68221","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"68222","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre open-label single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"68223","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"68224","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"68225","doi-asserted-by":"crossref","unstructured":"Cvetkovic RS, Keating G. Anakinra. BioDrugs. 2002; 16(4):303-311.","DOI":"10.2165\/00063030-200216040-00005"},{"key":"68226","unstructured":"Agency EM. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). 2024. Publisher Full Text|"},{"key":"68227","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Ciceri F. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT activity survey. Bone Marrow Transplant. 2023; 58(6):647-658.","DOI":"10.1038\/s41409-023-01943-3"},{"key":"68228","doi-asserted-by":"crossref","unstructured":"Bastos-Oreiro M, Gutierrez A, Reguera JL. Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO\/GETH Spanish groups. Front Immunol. 2022; 13:855730.","DOI":"10.3389\/fimmu.2022.855730"},{"key":"68229","doi-asserted-by":"crossref","unstructured":"Kwon M, Iacoboni G, Reguera JL. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023; 108(1):110-121.","DOI":"10.3324\/haematol.2022.280805"},{"key":"68230","doi-asserted-by":"crossref","unstructured":"Alexander M, Culos K, Roddy J. Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration. Transplant Cell Ther. 2021; 27(7):558-570.","DOI":"10.1016\/j.jtct.2021.01.014"},{"key":"68231","doi-asserted-by":"crossref","unstructured":"Hayden PJ, Roddie C, Bader P. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3):259-275.","DOI":"10.1016\/j.annonc.2021.12.003"},{"key":"68232","doi-asserted-by":"crossref","unstructured":"Gazeau N, Barba P, Iacoboni G. Safety and efficacy of two anakinra dose regimens for refractory CRS or Icans after CAR T-cell therapy. Blood. 2021; 138(Suppl 1):2816.","DOI":"10.1182\/blood-2021-147454"},{"key":"68233","doi-asserted-by":"crossref","unstructured":"Jain T, Knezevic A, Pennisi M. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787.","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"68234","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Sesques P. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.","DOI":"10.1182\/blood.2020010543"},{"key":"68235","doi-asserted-by":"crossref","unstructured":"Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy - A brief review of a complex problem. Cancers (Basel). 2022; 14(6):1501.","DOI":"10.3390\/cancers14061501"},{"key":"68236","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Koenecke C. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023; 11(4):e006406.","DOI":"10.1136\/jitc-2022-006406"},{"key":"68237","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Wulf GG, Duell J. Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA\/DRST study. Blood Adv. 2023; 7(4):555-559.","DOI":"10.1182\/bloodadvances.2022008042"},{"key":"68238","doi-asserted-by":"crossref","unstructured":"Rejeski K, Burchert A, Iacoboni G. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022; 6(16):4719-4725.","DOI":"10.1182\/bloodadvances.2022007776"},{"key":"68239","doi-asserted-by":"crossref","unstructured":"Bethge WA, Martus P, Schmitt M. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022; 140(4):349-358.","DOI":"10.1182\/blood.2021015209"},{"key":"68240","doi-asserted-by":"crossref","unstructured":"Dreger P, Holtick U, Subklewe M. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience. Bone Marrow Transplant. 2023; 58(2):229-232.","DOI":"10.1038\/s41409-022-01867-4"},{"key":"68241","doi-asserted-by":"crossref","unstructured":"Greco R, Alexander T, Del Papa N. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024; 69:102476.","DOI":"10.1016\/j.eclinm.2024.102476"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284810\/77104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284810\/77701","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11620\/77104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:31Z","timestamp":1794045991000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284810","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}